Tom,
I don't see Serologicals Corp as "competitor, customer or acquirer"
of Immucor.
Not a competitor because Sero is not into automation devices.
Not a customer: Sero's main revenue is in specialty antibodies which are gotten from doners in the blood doner centers the company owns. But SERO has their own manual blood typing test. Even though Sero's centers would benefit from the ABS, I don't think they would use a competitor's test.
Acquirer: Probably not, Sero says they are looking to acquire test sites. Blud would not fit this bill. BUT , Sero has been doing very well financially (stock doubled last year, stock split in Aug 1998, stock up again; earnings up over last 2 years) This company is growing. As I said above, Sero would benefit from using ABS ,Rosys, and /or Dias. because of the doner centers they own and need. I'm almost sure that these centers do more than just collect specialty antibodies. Remember, BLUD would be immediately accretive to Sero's bottom line in addition to providing needed technology. For about $350 million in cash Sero could buy BLUD. I believe Sero could get this kind of financing...not to mention that a combo. cash & stock swap deal could also be worked out. Anything is possible. Who knows what ideas will pop into the minds of corporate directors.
Dominic
|
